P-1183. Analysis of Cefiderocol use at an Academic Medical Center and Associated Patient Outcomes

P-1183. 学术医疗中心头孢地洛使用情况分析及相关患者结局

阅读:1

Abstract

BACKGROUND: Cefiderocol is a siderophore cephalosporin antibiotic approved for treatment of complicated urinary tract infections (cUTI), hospital-acquired bacterial pneumonia (HABP), and ventilator-associated bacterial pneumonia (VABP) caused by multidrug-resistant (MDR) gram-negative organisms. Banner University Medical Center – Phoenix (BUMCP) restricts cefiderocol use to specific MDR pathogens. Concerns exist about delayed initiation of cefiderocol due to limited rapid diagnostics, which may adversely affect patient outcomes. [Figure: see text] [Figure: see text] METHODS: A retrospective chart review of hospitalized patients receiving ≥1 dose of cefiderocol from January 2023 to July 2024 at BUMCP was conducted. Patients were evaluated for clinical appropriateness of cefiderocol use, timing of initiation, microbiological susceptibilities, and outcomes including 30-day mortality, re-infection, and readmission. [Figure: see text] RESULTS: Seventy-six patients were included. Cefiderocol was used primarily for CRE (63%) and CRAB (12%) infections. Most patients (96%) met BUMCP restriction criteria. Cefiderocol was used as definitive therapy in 68% of cases, with a median initiation time of 3 days post-culture. ID was consulted in 99% of cases. Thirty-day mortality was highest in CRAB infections (33%), consistent with CREDIBLE-CR trial findings. Susceptibility to cefiderocol was confirmed in 86% of organisms tested. Delays in susceptibility testing and inconsistent reporting of preferred agent susceptibilities were identified. CONCLUSION: Cefiderocol use at BUMCP is largely appropriate and reserved for high-risk MDR infections. Delayed initiation, often beyond the 48–72-hour window studied in clinical trials, may contribute to worse outcomes, particularly in CRAB infections. Implementation of routine CARBA-5 testing and reflex susceptibility panels may improve timely initiation. Further studies are needed to assess impact of diagnostic improvements on outcomes. DISCLOSURES: Emir Kobic, BCIDP, Shionogi: Honoraria

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。